Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-03-22
1998-11-24
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
426648, 426656, 514 13, 514 14, 514 15, 514 16, 514 17, 514 18, 530324, 530325, 530326, 530327, 530328, 530329, 530330, 530331, A61K 3806, A61K 3807, A61K 3808, A61K 3810
Patent
active
058406883
ABSTRACT:
Peptides corresponding to specific portions of the apolipoprotein A-IV (apo A-IV) are provided. Most of the peptides correspond to the amino terminal region of apo A-IV. In addition, those peptides corresponding to the amino terminal portion of apo A-IV substantially correspond to a fundamental repeat unit of twenty two amino acids comprising:
REFERENCES:
patent: 3832465 (1974-08-01), Ghadimi
patent: 5013722 (1991-05-01), Danho et al.
Boguski et al. (1984) "Rat Apolipoprotein A-IV Contains 13 Tandem Reptitions of a 22-Amino Acid Segment with Amphipathic Helical Potential," Proc. Natl. Acad. Sci. USA 81:5021-5025.
Boguski et al. (1986) "Evolution of Apolipoproteins," J. Biol. Chem. 261(14):6398-6407.
Fujimoto et al. (1992) "Increased Apolipoprotein A-IV in Rat Mesenteric Lymph After Lipid Meal Acts as a Physiological Signal for Satiation," Am. J. Physiol., pp. G1002-G1006.
Fujimoto et al. (1986) "Anorexia Induced in Rat by D-Glucosamine Deoxidized at C-1," Am. J. Physiol., pp. R481-R491.
Fujimoto et al. (1993) "Suppression of Food Intake by Apolipoprotein A-IV is Mediated Through the Central Nervous System in Rats," J. Clin. Invest. 91:1830-1833.
Fujimoto et al. (1993) "Effect of Intravenous Administration of Apolipoprotein A-IV on Patterns of Feeding , Drinking, and Ambulatory Activity of Rats," Brain Research 608:233-237.
Gordon et al. (1984) "Biosynthesis of Human Preaoplipoprotein A-IV," J. Biol. Chem. 259(1):468-474.
Haddad et al. (1986) "Linkage, Evolution, and Expression of the Rat Apolipoprotein A-I, C-III, and A-IV Genes," J. Biol. Chem. 261(28):13268-13277.
Karathanasis et al. (1986) "Structure, Evolution and Polymorphisms of the Human Apolipoprotein A4 Gene (APOA4)," Proc. Natl. Acad. Sci. USA 83:8457-8461.
Morley et al. (1987) "An Investigation of Tolerance to the Actions of Leptogenic and Anorexigenic Drugs in Mice," Life Sciences 41:2157-2165.
Shargill et al. (1991) "Enterostatin Suppresses Food Intake Following Injection Into the Third Ventricle of Rats," Brain Research 544:137-140.
Tso et al. (1991) "The Absorption and Transport of Lipids by the Small Intestine," Brain Research Bulletin 27:477-482.
Yang et al. (1989) "The Primary Structure of Human Apolipoprotein A-IV" Biochimica et Biophysica Acta. 1002:231-237.
Fujimoto et al. (1992) "Increased Apolipoprotein A-IV in Rats Mesenteric Lymph after Lipid Meal Acts as a Physiological Signal for Satiation" Amer. J. Physiol. 6(1):G1002-1006.
Miyoshi et al. (1978) "Deprotection of Protected Peptides" Chemical Abstracts 88(11):abstract No. 74543t.
Rexova et al. (1964) "Chemical Characterisation of Some Low Molecular Components of Honeybee Poison" Chemical Abstracts 60(12):abstract No. 14749d.
Van Vunakis et al. (1964) "Structural Studies on Pepsinogen and Pepsin: An Immunologic Approach" Chemical Abstracts 60(4):abstract No. 4407h.
Dimarchie et al. "Solid Phase Synthesis of the . . . Acid" Int. J. Pept. Protein Res. (1982) vol. 19, No. 3 pp. 270-279.
Research Corporation Technologies Inc.
Russel Jeffrey E.
LandOfFree
Eating suppressant peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Eating suppressant peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Eating suppressant peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1702190